High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

This article has a correction. Please see:

Correction: High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma - March 01, 2024

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma

Online download statistics by month:

Online download statistics by month: March 2024 to September 2025

	Abstract	Full	Pdf
Mar 2024	640	647	221
Apr 2024	416	419	117
May 2024	527	531	61
Jun 2024	292	296	76
Jul 2024	427	428	62
Aug 2024	230	235	54
Sep 2024	252	252	70
Oct 2024	254	254	48
Nov 2024	262	263	57
Dec 2024	278	281	47
Jan 2025	299	302	52
Feb 2025	354	356	49
Mar 2025	191	191	67
Apr 2025	268	268	73
May 2025	263	266	79
Jun 2025	198	200	52
Jul 2025	1	1	0
Aug 2025	1	1	0
Sep 2025	1	1	0
Total	5154	5192	1185